Navigation Links
Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
Date:1/21/2009

Simultaneous Studies to Investigate Novel Therapy for Ulcerative Colitis and Crohn's Disease

OSAKA, Japan, Jan. 22 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") announced today that its wholly-owned subsidiary, Millennium Pharmaceuticals, Inc., has initiated two Phase III clinical trials for vedolizumab (MLN0002), an investigational compound for inflammatory bowel disease (IBD). The trials, known as the GEMINI(TM) program, will study vedolizumab for the treatment of ulcerative colitis and Crohn's disease, the two main types of IBD. Developed by Millennium, vedolizumab is a novel alpha4 beta7 integrin antagonist, a highly selective humanized monoclonal antibody.

"Dosing of the first patient in the Phase III development program of vedolizumab is an exciting milestone," said Brian Feagan, M.D., professor of Medicine at the University of Western Ontario, London, Canada and principal investigator of the GEMINI(TM) studies. "This treatment has great potential to improve the lives of patients with Crohn's disease and ulcerative colitis."

Though current IBD treatments have been effective for many patients with mild to moderate disease, a significant unmet need exists for those patients with moderate to severe IBD. Failure of current medical therapy for ulcerative colitis and Crohn's disease frequently leads to surgical removal of the colon in the case of ulcerative colitis, and multiple bowel resections in the case of Crohn's disease.

If approved by the U.S. Food and Drug Administration (FDA), commercialization of vedolizumab will be the responsibility of Takeda Pharmaceuticals North America, Inc., a subsidiary of Takeda Pharmaceutical Company Limited. Takeda has been a leader in gastroenterological therapies, such as Prevacid(R), for more than 10 years and is committed to bringing new therapies to market that may benefit patients.

"We are excited to a
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
2. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
5. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
6. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
7. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
8. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
9. Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
10. Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial ... quarter of 2015, the Company reported a net loss of $24.0 ... of $13.4 million, or $0.18 loss per share, for the same ... the Company reported a net loss of $25.2 million, or $0.30 ... or $0.35 loss per share, for the first half of last ...
(Date:7/29/2015)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ) today ... 2015 financial results after the market closes on Wednesday, ... by a conference call at 5:00 p.m. ET, which ... webcast. During the conference call, the company will review ... The conference call dial-in numbers are (877) ...
(Date:7/29/2015)... Calif., July 29, 2015  Depomed, Inc. (Nasdaq: ... achievements for the quarter ended June 30, 2015. ... the pain and neurology marketplace, with significant net product ... substantial value to our shareholders in both the immediate ... of Depomed. "Growth in the second quarter was led ...
Breaking Medicine Technology:Neurocrine Biosciences Reports Second Quarter 2015 Results 2Neurocrine Biosciences Reports Second Quarter 2015 Results 3Neurocrine Biosciences Reports Second Quarter 2015 Results 4Neurocrine Biosciences Reports Second Quarter 2015 Results 5Neurocrine Biosciences Reports Second Quarter 2015 Results 6Neurocrine Biosciences Reports Second Quarter 2015 Results 7Neurocrine Biosciences Reports Second Quarter 2015 Results 8Neurocrine Biosciences Reports Second Quarter 2015 Results 9Sangamo BioSciences Announces Second Quarter 2015 Conference Call and Webcast 2Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 2Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 3Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 4Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 5Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 6Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 7Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 8Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 9Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 10Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 11Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 12Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 13Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 14Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 15
... Beginning April 1, Highmark Blue Cross Blue Shield ... with primary immunodeficiency diseases and other rare disorders to ... (IgG - a blood plasma product), regardless of their ... patients who are being treated successfully with another brand ...
... ANGELES, March 21, 2011 Attorneys from Dallas, Heygood, Orr ... that will require executives from Watson Pharmaceuticals Inc. (NYSE: ... oath and produce key documents as part of a lawsuit over ... company,s fentanyl patch. Attorney Michael Heygood represents ...
Cached Medicine Technology:Despite New Changes, Highmark Policy Still Threatens Patients With Primary Immunodeficiency Diseases 2Despite New Changes, Highmark Policy Still Threatens Patients With Primary Immunodeficiency Diseases 3Heygood, Orr & Pearson: Los Angeles Court Orders Watson Pharmaceuticals to Produce Documents, Provide Depositions in Fentanyl Patch Death Lawsuit 2
(Date:7/30/2015)... ... July 30, 2015 , ... Summer is the dry ... Add to that a particularly long, dry and hot 2015 summer season and the ... fresh water advocate Sharon Kleyne will discuss the 2015 summer season and identify the ...
(Date:7/30/2015)... ... July 30, 2015 , ... The renowned Brain ... its history of funding brain aneurysm research. , Each year, the Brain ... toward scientific research directed at early detection, improved treatment modalities, and technological advances ...
(Date:7/30/2015)... ... ... PeopleKeys, a company with over 30 years of experience in behavioral analysis, today ... newest installment in their popular DISC for the Real World series, will air at ... is intended for people interested in training others to use DISC behavioral analysis as ...
(Date:7/29/2015)... ... , ... Drs. Hamstead are very excited to announce the expansion of ... in the clinic; massage therapy works very well alongside chiropractic care to restore balance ... AlignLife of Simpsonville to work alongside the doctors. Many people can benefit from massage ...
(Date:7/29/2015)... Los Angeles, CA (PRWEB) , ... July 29, 2015 , ... According to an ... published by the National Institutes of Health shows exactly what a person needs to do ... sex, height, and weight, the app will give informed estimates as to the number of ...
Breaking Medicine News(10 mins):Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 2Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 4Health News:PeopleKeys to Air “Managing Stress: Train the Trainer” DISC Webinar 2Health News:AlignLife of Simpsonville Hires Massage Therapist 2Health News:New NIH Body Weight Planner Illustrates the Need for Reduced Caloric Intake When Trying to Lose Weight, Says Beverly Hills Physicians 2
... Help Kids Worldwide, NEW YORK, Feb. 4 ... are being asked to submit creative,drawings for the 2008 ... One winner will be chosen from thousands of,entries and ... UNICEF,holiday greeting card, sold exclusively at Pier 1 Imports ...
... YORK, February 4, 2008 The Juvenile Diabetes ... of type 1 diabetes research, announced today that ... company based in Winston-Salem, N.C. that focuses on ... Through its Industry Discovery and Development Partnership Program, ...
... Feb. 4 Renowned esthetician, Karen,Dunlap, has developed ... recognized as the number-one most nutritious and powerful ... the dots between science and,nature, Dunlap discovered that ... -- magnifies its benefits. Her new signature facial, ...
... and 4 percent of former illicit drug users ... year following an organ transplant. These results are ... a journal by John Wiley & Sons. The ... ( http://www.interscience.wiley.com/journal/livertransplantation ). , Substance abuse can lead ...
... 2008 Contrary to previous research, older adults who use ... reduced risk of developing dementia or Alzheimers disease. This is ... the American Geriatrics Society that tracked patients using vitamin E ... than 5 years. The study also finds that the combined ...
... connecting patients and caregivers offers tips to families, ... ... helpful, CHICAGO, Feb. 4 What do you say, what ... or suffering from a serious,disease? To kick-off National Patient Recognition Week, ...
Cached Medicine News:Health News:Budding Young Artists Invited to Compete in 17th Annual Pier 1 Imports/UNICEF Greeting Card Contest 2Health News:Budding Young Artists Invited to Compete in 17th Annual Pier 1 Imports/UNICEF Greeting Card Contest 3Health News:JDRF partners with Plureon to explore generating insulin-producing cells from adult stem cells 2Health News:Breakthrough 'Acai Berry Anti-Aging Facial' Applies Benefits of Nature's Super-Food to the Skin 2Health News:Former substance abusers rarely relapse after organ transplantation 2Health News:Vitamin E or C does not reduce risk of dementia or Alzheimer's 2Health News:It's National Patient Recognition Week - Here's How You Can Do Something Special for Someone Facing Illness 2Health News:It's National Patient Recognition Week - Here's How You Can Do Something Special for Someone Facing Illness 3
... Stryker Universal Wedge Screw is ... in cruciate reconstruction and is ... BTB grafts. The Universal Wedge ... and has blunt threads which ...
... combination of a screw and a barbed pin. ... resorbable pins for a hammertoe fixation and prevents ... use! Drill and tap the proximal phalanx. Drill ... the implant proximally. Press fit the barbed portion ...
The Stryker Graft Workstation offers the surgeon flexibility in graft preparation. The posts are interchangeable and the system adapts to both soft tissue and bone grafts selection. Sizing gauges off...
... The Stryker Conquest Suture ... instruments that pierce through ... suture through the tissue ... The Conquest Retrievers are ...
Medicine Products: